Document is current
Any future updates will be listed below
-
Authors
Lei, Du
Li, Wenbin
Tallman, Maxwell J. https://orcid.org/0000-0003-3036-561X
Strakowski, Stephen M.
DelBello, Melissa P.
Rodrigo Patino, L.
Fleck, David E.
Lui, Su https://orcid.org/0000-0003-3541-1769
Gong, Qiyong https://orcid.org/0000-0002-5912-4871
Sweeney, John A. https://orcid.org/0000-0003-1752-2828
Strawn, Jeffrey R.
Nery, Fabiano G.
Welge, Jeffrey A.
Rummelhoff, Emily
Adler, Caleb M.
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (P50MH077138, R01MH080973, R01MH078043)
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health
AstraZeneca Pharmaceuticals
- License Information
-
More Information
Article History
Received: 14 December 2021
Revised: 17 March 2022
Accepted: 11 April 2022
First Online: 18 May 2022
Competing interests
: FGN spouse is an employee at Eli Lilly and Co. FGN himself reported no conflicts of interests. JRS has received research support from the National Institutes of Health (NIMH/NIEHS/NICHD) as well as AbbVie, Neuronetics, and Otsuka. He has received material support from and provided consultation to Myriad Genetics and receives royalties from the publication of two texts (Springer) and serves as an author for UpToDate and an Associate Editor for Current Psychiatry. He has spoken in CME presentations for Neuroscience Education Institute, MedScape, American Academy of Child & Adolescent Psychiatry, American Academy of Pediatrics, and CMEology. Finally, JRS also has provided consultation to the FDA and Intracellular Therapeutics. JAS consults to VeriSci. LRP has received research support from Acadia, Allergan, Janssen, Johnson and Johnson, Lundbeck, Otsuka, Pfizer, Sunovion and Supernus. MPD is on the lecture bureau for Sunovion; has received research support from Alkermes, Acadia, Allergan, Janssen, Johnson and Johnson, Lundbeck, Otsuka, Pfizer, Sunovion and Supernus; and has provided consultation or advisory board services for Alkermes, Allergan, Assurex, CMEology, Janssen, Johnson and Johnson, Lundbeck, Myriad, Neuronetics, Otsuka, Pfizer, Sunovion and Supernus. CMA has spoken for Otsuka and Janssen. He has received research support from Merck, Forest, and Alkermes, and provided consultation for Janssen. SMS chairs Data Safety and Monitoring Boards for Sunovion and has grant funding (through the University of Texas) from Janssen. All other authors declare that they have no potential conflicts of interest.
